all over again [1,000/mm:<50,000/mm 3 ):> 6 weeks but <8 weeks: Delay dose for up to 2 weeks and temporarily reduce dose to 11 mg/m 2 every 8 hours (33 mg/m 2 /day) for 3 days (99 mg/m 2 /cycle)> 8 weeks but <10 weeks: Assess for disease progression; if no disease progression, delay dose for up to 2 weeks and reduce dose to 11 mg/m 2 every 8 hours (33 mg/m 2 /day) for 3 days (99 mg/m 2 /cycle); maintain or increase dose with subsequent cycles if clinically indicated or 20 mg/m 2 over 1 hour daily for 5 days every 28 days (delay subsequent treatment cycles until hematologic recovery [ANC 1,000/mm 3 and platelets 50,000/mm 3 ]); treatment is recommended for at least 4 cycles and may continue until the patient no longer benefits. Acute myeloid leukemia (AML) (off-label use): Adults 60 years: IV: 20 mg/m 2 over 1 hour daily for 5 days every 28 days until relapse, disease progression, or unacceptable toxicity (Cashen 2010; Kantarjian 2012) Dosing: Geriatric Refer to adult dosing. Dosing: Renal Impairment Preexisting impairment: There are no dosage adjustments provided in the manufacturer s labeling (has not been studied); use with caution. Renal toxicity during treatment: Serum creatinine 2 mg/dL: Temporarily hold treatment until resolution. Dosing: Hepatic Impairment Preexisting impairment: There are no dosage adjustments provided in the manufacturer s labeling (has not been studied); use with caution. Hepatotoxicity during treatment: ALT and/or bilirubin 2 times ULN: Temporarily hold treatment until resolution. Dosing: Adjustment for Toxicity Hematologic toxicity (ANC> <1,000/mm 3 and platelets> <50,000/mm 3 ): Delay and/or reduce dose; refer to adult dosing for recommendations specific to each MDS dosing regimen Nonhematologic toxicity: Temporarily hold treatment until resolution for any of the following toxicities: Serum creatinine 2 mg/dL ALT, bilirubin 2 times ULN Active or uncontrolled infection Reconstitution Vials should be reconstituted with 10 mL SWFI to a concentration of 5 mg/mL. Immediately further dilute with NS or D5W to a final concentration of 0.1 to 1 mg/mL. Use appropriate precautions for handling and disposal. Solutions not administered within 15 minutes of preparation should be prepared with cold (2 C to 8 C [36 F to 46 F]) infusion solutions. Administration Infuse over 1 to 3 hours. For the treatment of myelodysplastic syndromes, administer by IV infusion over 3 hours (15 mg/m 2 dose) or over 1 hour (20 mg/m 2 dose). For the treatment of acute myeloid leukemia (off-label use), administer by IV infusion over 1 hour (Cashen 2010; Kantarjian 2012). Premedication with antiemetics is recommended according to the manufacturer. Storage Store intact vials at 25 C (77 F); excursions permitted to 15 C to 30 C (59 F to 86 F). Solutions diluted for infusion in NS or D5W may be stored for up to 4 hours prior to infusion refrigerated at 2 C to 8 C (36 F to 46 F) if prepared with cold infusion fluids. Infusion should begin within 15 minutes of preparation if room temperature infusion solutions are utilized. Drug Interactions BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Avoid combination CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Monitor therapy Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Avoid combination Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Avoid combination Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modification Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modification Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Consider therapy modification Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy Adverse Reactions> 10%: Cardiovascular: Peripheral edema (25% to 27%), edema (5% to 18%), heart murmur (16%), hypotension (6% to 11%) Central nervous system: Fatigue (46%), headache (23% to 28%), insomnia (14% to 28%), rigors (22%), dizziness (18% to 21%), chills (16%), pain (5% to 13%), confusion (8% to 12%), lethargy (12%), hypoesthesia (11%), anxiety (9% to 11%) Dermatologic: Pallor (23%), skin rash (11% to 19%), erythema (5% to 14%), cellulitis (9% to 12%), pruritus (9% to 11%) Endocrine & metabolic: Hyperglycemia (6% to 33%), hypoalbuminemia (7% to 24%), hypomagnesemia (5% to 24%), hypokalemia (12% to 22%), hyponatremia (19%), hyperkalemia (13%) Gastrointestinal: Nausea (40% to 42%), constipation (30% to 35%), diarrhea (28% to 34%), vomiting (16% to 25%), anorexia ( 8% to 23%), decreased appetite ( 8% to 23%), abdominal pain (5% to 14%), stomatitis (11% to 12%), dyspepsia (10% to 12%) Hematologic & oncologic: Neutropenia (38% to 90%; grades 3/4: 37% to 87%; recovery 28 to 50 days), thrombocytopenia (27% to 89%; grades 3/4: 24% to 85%), anemia (31% to 82%; grades 3/4: 22%), petechia (12% to 39%), febrile neutropenia (20% to 29%; grades 3/4: 23%), leukopenia (6% to 28%; grades 3/4: 22%), bruise (9% to 22%), oral mucosal petechiae (13%), lymphadenopathy (12%) Hepatic: Hyperbilirubinemia (6% to 14%), increased serum alkaline phosphatase (11%) Local: Localized tenderness (11%) Neuromuscular & skeletal: Arthralgia (17% to 20%), limb pain (18% to 19%), back pain (17% to 18%), weakness (15%) Respiratory: Cough (27% to 40%), dyspnea (29%), pneumonia (20% to 22%), pharyngitis (16%), rales (8% to 14%), epistaxis (13%) Miscellaneous: Fever (6% to 53%), lesion (5% to 11%) 5% to 10%: Cardiovascular: Tachycardia (8%), chest wall pain (7%), chest pain ( 6% to 7%), chest discomfort ( 6% to 7%), facial edema (6%), hypertension (6%), cardiac failure (5%) Central nervous system: Depression (9%), falling (8%), malaise (5%), mouth pain (5%) Dermatologic: Alopecia (8%), xeroderma (8%), urticaria (6%), catheter site erythema (5%), night sweats (5%) Endocrine & metabolic: Hyperuricemia (10%), weight loss (9%), increased lactate dehydrogenase (8%), dehydration (6% to 8%), hypochloremia (6%), increased serum bicarbonate (6%), decreased serum bicarbonate (5%), hypoproteinemia (5%) Gastrointestinal: Mucosal inflammation (9%), gingival hemorrhage (8%), hemorrhoids (8%), loose stools (7%), tongue ulcer (7%), oral candidiasis (6%), toothache (6%), dysphagia (5% to 6%), abdominal distention (5%), gastroesophageal reflux disease (5%), glossalgia (5%), oral mucosa ulcer (lip: 5%) Genitourinary: Urinary tract infection (7%), dysuria (6%) Hematologic & oncologic: Hematoma (5%), pancytopenia (5%), thrombocythemia (5%) Hepatic: Ascites (10%), increased serum AST (10%), decreased serum bilirubin (5%) Hypersensitivity: Transfusion reaction (7%) Infection: Candidiasis (10%), bacteremia (5% to 8%), staphylococcal infection (7%), tooth abscess (5%) Local: Catheter infection (8%), catheter pain (5%), swelling at injection site (5%) Neuromuscular & skeletal: Myalgia (5% to 9%), muscle spasm (7%), ostealgia (6%), musculoskeletal pain ( 6%; includes discomfort) Ophthalmic: Blurred vision (6%) Otic: Otalgia (6%) Renal: Polyuria (5%) Respiratory: Hypoxia (10%), upper respiratory tract infection (10%), abnormal breath sounds (5% to 10%), pharyngolaryngeal pain (8%), pulmonary edema (6%), sinusitis (5% to 6%), pleural effusion (5%), post nasal drip (5%), pulmonary signs and symptoms (crepitations: 5%), sinus congestion (5%) <5% (Limited to important or life-threatening): Abscess (peridiverticular), acute cardiorespiratory failure, anaphylaxis, atrial fibrillation, cardiomyopathy, catheter site hemorrhage, cholecystitis, fungal infection, gastrointestinal hemorrhage, gingival pain, hemoptysis, hypersensitivity reaction, intracranial hemorrhage, mental status change, myocardial infarction, mycobacterium avium complex, nodule (pulmonary), pulmonary aspergillosis, pulmonary embolism, pulmonary infection (pseudomonas), pulmonary infiltrates, renal failure, sepsis, splenomegaly, supraventricular tachycardia, Sweet s syndrome (acute febrile neutrophilic dermatosis), urethral bleeding Warnings/Precautions Concerns related to adverse effects: Bone marrow suppression: Neutropenia and thrombocytopenia commonly occur; anemia and neutropenic fever have also been reported. Myelosuppression and worsening neutropenia are more common in first two treatment cycles and may not correlate with progression of underlying MDS. Hematologic toxicity may require dosage adjustment (after the first cycle), growth factor support, and/or antimicrobial agents. Monitor for infection. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Monitoring Parameters CBC with differential and platelets (with each cycle and more frequently if needed); liver enzymes (prior to treatment initiation and periodically); serum creatinine (prior to treatment initiation and periodically) Pregnancy Risk Factor D Pregnancy Considerations Adverse events were observed in animal reproduction studies. Based on the mechanism of action, decitabine may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to use effective contraception to avoid pregnancy during treatment and for 1 month after treatment. In addition, males should be advised to avoid fathering a child while on decitabine therapy and for 2 months after treatment. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience dizziness, abdominal pain, nausea, vomiting, mouth sores, pinpoint red spots on skin, constipation, diarrhea, insomnia, lack of appetite, headache, itching, muscle pain, joint pain, anxiety, hair loss, or back pain. Have patient report immediately to prescriber signs of infection, signs of bleeding (vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe bleeding or persistent bleeding), signs of high blood sugar (confusion, fatigue, more thirst, hunger, polyuria, flushing, fast breathing, or breath that smells like fruit), signs of fluid and electrolyte problems (mood changes, confusion, muscle pain or weakness, abnormal heartbeat, severe dizziness or passing out, tachycardia, more thirst, seizures, loss of strength and energy, lack of appetite, urinary retention or change in amount of urine produced, dry mouth, dry eyes, or nausea or vomiting), severe loss of strength and energy, pale skin, jaundice, swollen glands, shortness of breath, edema, blurred vision, difficulty swallowing, angina, tachycardia, or numbness and tingling (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about decitabine Side Effects During Pregnancy Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 0 Reviews Add your own review/rating Drug class: antimetabolites Consumer resources Decitabine Decitabine Intravenous (Advanced Reading) Professional resources Decitabine (AHFS Monograph) Decitabine (FDA) Other brands: Dacogen Related treatment guides Acute Myeloid Leukemia Myelodysplastic Syndrome> ]} Drug Status Rx Availability Prescription only D Pregnancy Category Positive evidence of risk N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Decitabine Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Manufacturers Dr. Reddy's Laboratories, Inc. Sun Pharmaceutical Industries Inc. Drug Class Antimetabolites Related Drugs antimetabolites methotrexate , fluorouracil , hydroxyurea , Xeloda , capecitabine , Hydrea Myelodysplastic Syndrome Vidaza , azacitidine , Dacogen , More...} } decent
the hand made Decitabine that you're the
EmoticonEmoticon